CA2352526A1 - Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system - Google Patents

Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system Download PDF

Info

Publication number
CA2352526A1
CA2352526A1 CA002352526A CA2352526A CA2352526A1 CA 2352526 A1 CA2352526 A1 CA 2352526A1 CA 002352526 A CA002352526 A CA 002352526A CA 2352526 A CA2352526 A CA 2352526A CA 2352526 A1 CA2352526 A1 CA 2352526A1
Authority
CA
Canada
Prior art keywords
azabicyclo
exo
ethyl
fluorophenyl
heptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352526A
Other languages
English (en)
French (fr)
Inventor
Gerd Steiner
Rainer Munschauer
Gerhard Gross
Martin Traut
Liliane Unger
Hans-Jurgen Teschendorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2352526A1 publication Critical patent/CA2352526A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002352526A 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system Abandoned CA2352526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19854147.3 1998-11-24
DE19854147A DE19854147A1 (de) 1998-11-24 1998-11-24 Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht
PCT/EP1999/008734 WO2000030639A1 (de) 1998-11-24 1999-11-12 Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems

Publications (1)

Publication Number Publication Date
CA2352526A1 true CA2352526A1 (en) 2000-06-02

Family

ID=7888824

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352526A Abandoned CA2352526A1 (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system

Country Status (21)

Country Link
EP (1) EP1133293A1 (no)
JP (1) JP2002530333A (no)
KR (1) KR20010080535A (no)
CN (1) CN1328455A (no)
AR (1) AR021502A1 (no)
AU (1) AU1775300A (no)
BG (1) BG105549A (no)
BR (1) BR9915589A (no)
CA (1) CA2352526A1 (no)
CZ (1) CZ20011796A3 (no)
DE (1) DE19854147A1 (no)
HK (1) HK1040933A1 (no)
HR (1) HRP20010472A2 (no)
HU (1) HUP0104416A3 (no)
IL (1) IL143181A0 (no)
NO (1) NO20012538L (no)
PL (1) PL348758A1 (no)
SK (1) SK7112001A3 (no)
TR (1) TR200101476T2 (no)
WO (1) WO2000030639A1 (no)
ZA (1) ZA200103976B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096560B2 (en) 2008-07-03 2015-08-04 Syngenta Limited 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519013A2 (pt) 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
BR112015016992A8 (pt) * 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004311A1 (en) * 1987-11-12 1989-05-18 American Home Products Corporation Polycyclicamines with psychotropic activity
DE4427648A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
DE4427647A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096560B2 (en) 2008-07-03 2015-08-04 Syngenta Limited 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides

Also Published As

Publication number Publication date
KR20010080535A (ko) 2001-08-22
NO20012538D0 (no) 2001-05-23
HRP20010472A2 (en) 2003-04-30
JP2002530333A (ja) 2002-09-17
DE19854147A1 (de) 2000-05-25
CZ20011796A3 (cs) 2002-05-15
BR9915589A (pt) 2001-08-07
SK7112001A3 (en) 2001-12-03
AU1775300A (en) 2000-06-13
BG105549A (en) 2001-12-29
PL348758A1 (en) 2002-06-03
HUP0104416A3 (en) 2002-11-28
ZA200103976B (en) 2002-05-16
TR200101476T2 (tr) 2001-10-22
HK1040933A1 (zh) 2002-06-28
IL143181A0 (en) 2002-04-21
WO2000030639A1 (de) 2000-06-02
AR021502A1 (es) 2002-07-24
HUP0104416A2 (hu) 2002-04-29
EP1133293A1 (de) 2001-09-19
NO20012538L (no) 2001-07-04
CN1328455A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
Mauri et al. Clinical pharmacology of atypical antipsychotics: an update
ES2246487T3 (es) Reboxetina para tratar la neuropatia periferica.
Liu et al. 5‐HT6 antagonists as potential treatment for cognitive dysfunction
KR20160005341A (ko) Ampk 활성인자 및 세로토닌성 제제를 포함하는 약학 조성물 및 이의 사용 방법
AU2001282734B2 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
TW201002701A (en) Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
CA2332814C (en) Combination therapy for treatment of refractory depression
HRP20000798A2 (en) Combination therapy for treatment of bipolar disorders
CN101198323A (zh) 用于治疗或预防精神障碍的治疗组合
KR100397525B1 (ko) 뇌혈관 장해에 수반되는 정신증후치료제
Love et al. Pharmacology and clinical experience with risperidone
WO2018148737A1 (en) 5-ht2a serotonin receptor serotonin receptor inverse agonists useful for the prophylaxis and treatment of parkinsonian symptoms associated with a neurodegenerative disease
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
CA2352526A1 (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
Steiner et al. D4/5-HT2A Receptor antagonists: LU-111995 and other potential new antipsychotics in development
MXPA01005104A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
WO1998037893A1 (fr) Antagoniste du recepteur dopaminergique d4
WO2018102824A1 (en) Methods for treating neurodegenerative disease
Slassi et al. Novel serotonergic and non-serotonergic migraine headache therapies
Rahman et al. Central & Peripheral Nervous System: 5-HT3 receptor antagonists
Reuter et al. Lasmiditan hydrochloride
Kent Clinical Pharmacology of New Classes of Antidepressant Drugs
WO2006034788A1 (en) Combinations of n-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors
CN101547927A (zh) 8-磺酰基-1，3，4，8-四氢-2h-[1，4]氧氮杂并[6，7-e]吲哚衍生物和它们作为5-ht6受体配体的应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued